Nasdaq: $29.63 (+0.33) | AIM: £4.32 (-0.06)
News & Presentations
Previous Article   |   Next Article
Oncology / Immunology, RNS Announcements | 22 Nov 2007

Chi-Med Plans to Initiate Global Phase IIb Trials of its Lead Anti-Inflammatory Drug Candidate, HMPL-004, in Ulcerative Colitis Patients

1 items
a071122